Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respreeza/Zemaira dose-ranging maintenance study in alpha1 antitrypsin deficiency-related emphysema
2025-522964-33-00Phase 4Authorised
- Sponsor
- CSL Behring
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) and emphysema (3 arms), sponsored by CSL Behring. Primary endpoint: Annual rate of change in adjusted lung density. Planned start Sep 2026; status: authorised.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2025-522964-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522964-33-00.